DETAILED ACTION
This action is in response to Applicant’s submission dated January 2, 2026, in which Applicant amended claims 1 and 41, and elected the invention of Group I and a species both without traverse.
Information Disclosure Statement
The references contained in the IDS dated July 16, 2025 are made of record.
Election/Restriction
Claims 1, 3-5, 7, 10-13, 16-17, 20, 29-30, 32, 36-37, 39, and 41-45 (all in part) withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a non-elected Group II, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on January 2, 2026.
The requirement is still deemed proper and is therefore made FINAL.
Claims 1, 3-5, 7, 10-13, 16-17, 20, 29-30, 32, 36-37, 39, and 41-45 (all in part) are examined. A complete reply to the final rejection must include cancellation of non-elected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.
Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claims 7, 39, and 45 are rejected under 35 U.S.C. 112(b), as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
Claim 7 lacks antecedent basis because it refers to F-1, F-2, or F-3, subject matter which does not appear in claim 1. Correction is required.
Claim 39 lacks antecedent basis because claim 1 lacks “CD3” as an option. Correction is required.
Claim 45 lacks antecedent basis because it is missing the claim to which it depends from. Correction is required.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1, 13, 16-17, 20, 32, 36-37, 39, and 42-45 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Liu, et al, Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors, ACS Medicinal Chemistry Letters, 10(3), pp. 383-388 (2019). Liu, et al. teaches a 6-anilino imidazopyridazine based Tyk2 JH2 ligand, which include instant compounds. Specifically, the compound:
PNG
media_image1.png
184
324
media_image1.png
Greyscale
of the reference anticipates the aforementioned claims where X is CR2, Q is
PNG
media_image2.png
64
92
media_image2.png
Greyscale
, R1 is 6-member heteroaryl ring substituted with oxo and 6-membered heteroaryl ring (pyridyl), R2 is H, L1 is NR10, R10 is H, R3 is methyl, R4 and R5 are both methyl, R6 is H, and L2 is a bond. The references compounds exhibit the same activity as the compounds of the instant claims.
Claims 1, 13, 16-17, 29, 36-37, 39, and 42-45 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Weinstein, et al, WO 2017/087590. Weinstein, et al. teaches preparation of imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INFα responses, which include instant compounds. Specifically, the compounds:
PNG
media_image3.png
258
382
media_image3.png
Greyscale
,
PNG
media_image4.png
250
356
media_image4.png
Greyscale
,
PNG
media_image5.png
246
358
media_image5.png
Greyscale
,
PNG
media_image6.png
230
354
media_image6.png
Greyscale
and
PNG
media_image7.png
226
362
media_image7.png
Greyscale
of the reference anticipates the aforementioned claims where X is CR2, Q is
PNG
media_image2.png
64
92
media_image2.png
Greyscale
, R1 is substituted aryl ring (mono or bicyclic), R2 is H, L1 is NR10, R10 is H, R3 is methyl, R4 and R5 are both optionally substituted methyl (with hydroxy), R6 is H, and L2 is O or methylene. The references compounds exhibit the same activity as the compounds of the instant claims.
Claims 1, 13, 16-17, 20, 32, 36-37, 39, and 42-45 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Liu, et al, WO 2015/089143. Liu, et al. teaches the preparation of imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFNα, which include instant compounds. Specifically, the compounds:
PNG
media_image8.png
238
378
media_image8.png
Greyscale
PNG
media_image9.png
238
400
media_image9.png
Greyscale
and
PNG
media_image10.png
204
346
media_image10.png
Greyscale
of the reference anticipates the aforementioned claims where X is CR2, Q is cyclohexyl or cyclopentyl, R1 is 6-member heteroaryl ring (pyridyl) substituted with oxo, R2 is H, L1 is NR10, R10 is H, and R3 is methyl. The references compounds exhibit the same activity as the compounds of the instant claims.
Claims 1, 13, 16, 32, 37, and 42 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hartz, et al, WO 2015/026574. Hartz, et al. teaches imidazopyridazine kinase inhibitors useful for treating a disease or disorder mediated by AAK1, which include instant compounds. Specifically, the compounds:
PNG
media_image11.png
268
470
media_image11.png
Greyscale
and
PNG
media_image12.png
224
536
media_image12.png
Greyscale
of the reference anticipates the aforementioned claims where X is CR2, Q is substituted 6-membered aryl or heteroaryl (pyrimidine), R1 is 6-member heterocycle ring substituted with amino, R2 is H, L1 is NR10, R10 is H, and R3 is phenyl or cyclopropyl. The references compounds exhibit the same activity as the compounds of the instant claims.
Claims 1, 13, 16, 37, and 42-45 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Fink, et al, WO 2009/100375. Fink et al. teaches the preparation of substituted imidazopyridazines as kinase inhibitors, which include instant compounds. The Specifically, the compounds:
PNG
media_image13.png
206
376
media_image13.png
Greyscale
PNG
media_image14.png
242
340
media_image14.png
Greyscale
PNG
media_image15.png
218
368
media_image15.png
Greyscale
PNG
media_image16.png
274
400
media_image16.png
Greyscale
PNG
media_image17.png
198
390
media_image17.png
Greyscale
of the reference anticipates the aforementioned claims where X is CR2, Q is a 6-membered heteroaryl optionally substitued with halogen (chlorine or fluorine), R1 is 6- or 7-membered heterocycle ring or phenyl, R2 is H, L1 is a bond or C2-3-heteroalkyelene, R10 is H, and R3 is cyclopropyl. The references compounds exhibit the same activity as the compounds of the instant claims.
Claim Objections
Claims 3-5, 10-12, 30, and 41 are objected to as being dependent upon rejected independent claim 1, but would be allowable if rewritten in independent form including all of the limitations of the base claims and any intervening claims.
Conclusion
Any inquiry concerning this communication or earlier communications from the Examiner should be directed to ERICH A LEESER whose telephone number is (571) 272-9932. The Examiner can normally be reached Monday through Friday from 10-6 PST, M-F. PST.
If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Mr. James Alstrum-Acevedo can be reached at (571) 272-5548. The fax number for the organization where this application is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) toll-free at 866-217-9197. If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ERICH A LEESER/Primary Examiner, Art Unit 1622
United States Patent and Trademark Office
Tel. No.: (571) 272-9932